# Seeing the Problem Before It Happens: How Carotid Ultrasound Helps Predict Heart Attacks and Strokes Carotid ultrasound is a safe, painless imaging test that measures the buildup of fatty plaque in the neck arteries, giving doctors a direct window into your risk for future heart attacks and strokes. This review of decades of research, conducted by Swiss and German specialists, shows that measuring carotid plaque—rather than relying only on traditional risk factors like cholesterol and blood pressure—can more accurately identify people who will experience cardiovascular events. The research demonstrates that carotid plaque measurement performs just as well as coronary calcium scoring (a widely used heart imaging test) and can help reclassify patients who are mistakenly labeled "low risk" by standard risk calculators. # Seeing the Problem Before It Happens: How Carotid Ultrasound Helps Predict Heart Attacks and Strokes ## Table of Contents - Key Points - Why This Research Matters: The Limits of Traditional Risk Assessment - How Carotid Ultrasound Works: A Closer Look at the Technology - What the Research Shows: Carotid Ultrasound and Health Outcomes - Carotid Plaque vs. Coronary Calcium: Head-to-Head Comparisons - Can Medical Treatment Reverse or Slow Carotid Atherosclerosis? - What Should Be Measured: IMT, Plaque, or Calcium? - Clinical Implications: What This Means for You - Limitations: What the Research Cannot Tell Us - Recommendations for Patients - Frequently Asked Questions - Source Information ## Key Points - Carotid plaque presence is a stronger predictor of heart attacks and strokes than IMT alone, according to multiple large studies. - Carotid ultrasound performs as well as coronary calcium scoring for predicting cardiovascular events, but without any radiation exposure. - In the MESA study, only carotid plaque presence—not coronary calcium or IMT—predicted stroke or transient ischemic attack after 9.5 years. - A meta-analysis of 41 randomized trials found that active treatment reduces cardiovascular events even when IMT does not visibly change. - European ESC guidelines now say carotid artery scanning should be considered for adjusting risk level, especially in intermediate-risk patients. ## Why This Research Matters: The Limits of Traditional Risk Assessment Whenever illness or injury strikes, a fundamental question arises: could it have been prevented? Identifying factors that predict future risk—so that risk can be managed and reduced—has been the focus of extensive ongoing research worldwide. The landmark INTERHEART study showed that major independent cardiovascular risk factors contribute to **90% of cardiovascular events** (heart attacks, strokes, and related conditions). According to the Swiss Federal Statistical Office, cardiovascular and cancer diseases remained the leading causes of mortality in Switzerland in 2015. The National Health Accounts showed that healthcare spending was highest for cardiovascular disease at **15.6%**, and together with cancer, these conditions accounted for **22% of healthcare expenditure** in Switzerland. Prevention of atherosclerosis-related diseases is therefore a primary healthcare priority. Traditionally, primary care physicians assess atherosclerosis risk by checking patients for traditional risk factors. The modification of just seven risk factors—**smoking, high blood pressure, high cholesterol, obesity, sedentary lifestyle, poor nutrition, and diabetes mellitus**—has great potential to prevent premature illness and death in the population. However, there is a critical problem: **many patients who arrive at the hospital with a first ischemic event (heart attack or stroke) were previously classified as "low risk"** by standard risk calculators such as PROCAM and SCORE. This means the calculators are missing people who are actually in danger. The authors of this review previously studied populations in Olten (Switzerland) and Koblenz (Germany) and found that the sensitivity of global risk calculators like PROCAM and SCORE is low for detecting advanced carotid atherosclerosis when measured as total carotid plaque area. They also found that the agreement between PROCAM and SCORE regarding risk categories is limited. This means two different risk calculators can label the same patient differently—a confusing and potentially dangerous situation. Direct visualisation of atherosclerosis (the actual buildup of plaque in the arteries) may therefore be warranted to reclassify individuals according to their true personal risk. ## How Carotid Ultrasound Works: A Closer Look at the Technology Carotid ultrasound is performed with a linear array probe—a handheld device placed on the neck—using a high frequency of **at least 7 MHz** to obtain sufficient resolution to image small structures. The image resolution depends on the depth and frequency used and is typically around **0.3 mm**. The anatomical region of interest is the **tunica intima** (the innermost layer of the artery wall), which is assessed with 2D imaging without Doppler. **Intima-media thickness (IMT)** is the distance between the endothelium (the thin cell layer lining the artery) and the tunica adventitia (the outer layer of the vessel wall). According to the Mannheim consensus (an international agreement on measurement standards), IMT is preferably measured in the far wall segment of the last 10 mm of the common carotid artery. One major challenge with carotid IMT measurements lies in the diversity of methods used across different studies. The variability of measurements is lowest in the far wall of the common carotid artery when plaque is excluded—but this gain in reproducibility comes at a cost: a **loss in predictive power for cardiovascular events**. **Total plaque area (TPA)** is the sum of the longitudinal area of all plaques in the carotid wall. It is measured from the clavicles to the jaws using multiple angles to capture the full extent of plaque in the carotid tree, including the proximal brachial artery if possible. More recently, **total plaque volume (TPV)** has become available using the Philips iU 22 ultrasound system equipped with a single-sweep volumetric transducer, which covers 3.8 cm of the carotid artery and visualises the distal part of the common carotid artery, the bulb, and the proximal parts of the internal carotid artery. Offline software calculates the plaque areas from all obtained transversal images to determine the total plaque volume. **The key advantages of TPA measurements include:** - High reproducibility (consistent results when repeated) - Vendor independence (no additional costs for surface tracing software) - Results can be obtained without additional software - Captures more plaque than TPV, which may miss plaques located outside its 3.8 cm field of view However, TPV can detect plaques located laterally in the vessel that may not be visible with the TPA method, so combining both approaches provides the most complete picture. The correlation between TPA and TPV is very strong, with a correlation coefficient of r² = 0.921 (p <0.0001). For clinical purposes, plaque is most commonly defined as an **IMT increase of more than 1.5 mm** or a **focal thickening of more than 50% compared with adjacent structures**. However, the definition of atherosclerotic plaque versus non-atherosclerotic intimal thickening has not been used uniformly in the medical literature. Researchers have used a wide variety of measurement approaches: - IMT increase >1.0 mm (Spence 1991) - Doubling of IMT (Spence 1991; Mannheim Consensus) - IMT thickening >1.2 mm (Handa) - Subjective assessment (Polak) - Encroachment into the lumen by 0.5 mm (Mannheim Consensus) - IMT increase ≥1.5 mm (Mannheim Consensus; Spence) - Texture changes (Singh) - Plaque present or absent (Nambi) - Number of plaques (Plichart) - Plaque thickness in mm (Rundek) - Plaque area in mm² (Spence) - Plaque volume in mm³ (Baber) - Echo lucency using gray scale (Stein) - Plaque vascularity using contrast agents (Coli) This lack of standardization has made it difficult to compare results across studies and apply them consistently in clinical practice. ## What the Research Shows: Carotid Ultrasound and Health Outcomes Outcome studies examining the relationship between the amount of carotid atherosclerosis and the incidence of heart and brain ischemic events are numerous. The largest ones include at least 4,000 subjects in cohort studies. Below are the key findings from these major studies. One of the first studies on the prognostic impact of atherosclerosis imaging using carotid ultrasound was published in **1991**. In **1,288 Finnish men**, coronary event risk increased compared with structural changes: **2.2-fold for intimal thickening** (not statistically significant), **4.2-fold for small carotid plaques** (p <0.01), and **6.7-fold for stenotic plaque** (p <0.01). In other words, the more advanced the plaque, the dramatically higher the risk of a heart event. In **1995**, Japanese researchers found that carotid stenosis (narrowing) and plaque ulcerations were predictive for ischemic stroke. In **1996**, Belcaro and colleagues found that increases in plaque burden in carotid and femoral arteries predicted cardiovascular events and death in **2,322 asymptomatic subjects** after a follow-up of 6 years. This was later confirmed in the CAFES-CAVE study of **13,221 low-risk subjects** after 10 years of follow-up. Spence showed in **2002** that total plaque area (TPA) was predictive for cardiovascular events, with increasing risk in the higher quartiles (quarters) of TPA. The analysis included **1,686 patients**, most of whom had experienced a previous stroke or transient ischemic attack (a "mini-stroke"). Of these, 684 were originally primary care patients. For these patients, adding posterior test probabilities based on Bayes' theorem (a mathematical approach to updating risk estimates) improved discrimination for predicting future heart attacks after 3.3 years of follow-up: the area under the curve (AUC, a measure of how well a test discriminates between those who will and won't have an event) improved from **0.68 for the standard NCEP III risk model to 0.75 for TPA-based posterior probability (p = 0.038)**. In **2003**, Hollander reported on **6,913 prospectively followed healthy subjects** in the Rotterdam study and found that carotid IMT (including regions with carotid plaque) was a **stronger predictor of future stroke than carotid plaque alone**. In **2004**, Van der Meer reported on **6,389 subjects** from the Rotterdam study and found that carotid structural changes (carotid and femoral plaque, carotid IMT including plaque, and aortic plaque) had **equal predictive power for subsequent heart attack**. In **2007**, Stein and colleagues reported on **6,226 originally healthy subjects** from the Norwegian Tromsø study. They found that TPA was a **stronger, statistically significant marker for heart attack than IMT, especially in women**, after correcting for several conventional cardiovascular risk factors. This observation remained significant after an extended follow-up of 15 years. In a smaller study from China, Xie and colleagues screened **1,734 subjects** for future heart attack and stroke and found that **all measures of structural changes in the carotid arteries** (IMT measured at six sites, TPA, and number of plaques) were effective for risk prediction after adjusting for conventional cardiovascular risk factors. In **2010**, Lorenz reported on the atherosclerosis progression study including **4,904 low-risk patients** with 10 years of follow-up. Carotid IMT derived from the common carotid artery, the bulb, and the internal carotid artery was **less predictive than the Framingham and SCORE risk models**—but notably, only 5% of these subjects had carotid plaques, which may explain the weaker performance. Also in **2010**, Chambless published results from the Atherosclerosis Risk in Communities (ARIC) study, in which **13,145 subjects** were followed for 15 years. The AUC increased **significantly** with the addition of carotid IMT or carotid plaque to traditional risk factors. In **2011**, Mathiesen and colleagues reported on **6,584 subjects** in the Tromsø study and found that **TPA—but not common carotid IMT—was predictive for incident ischemic stroke** after multivariate adjustment. In the same year, Polak reported that in **2,965 members of the Framingham Offspring Study** followed for 7 years, both internal carotid IMT and internal carotid plaque formation (defined as IMT ≥1.5 mm) **significantly improved the AUC** compared with the Framingham risk equation alone. ### Major Outcome Studies Using Carotid IMT and Plaque The following are the key large-scale studies (each with at least 4,000 participants) that examined how well carotid artery measurements predict heart attacks and strokes. A hazard ratio (HR) above 1.0 means higher risk; the confidence interval (CI) shows the range of uncertainty around that estimate. If the CI does not include 1.0, the result is statistically significant. - **CAFES-CAVE (10,000 subjects):** Mortality with no plaque: 0.1% events. With carotid plaque: 3.0% events. - **Rotterdam study (6,389 subjects):** Heart attack risk with plaque present vs. absent: HR 1.6 (95% CI 1.2–2.2). - **Rosvall (5,163 subjects):** Heart attack risk with plaque: HR 1.8 (95% CI 1.5–2.9). IMT top vs. bottom third: HR 1.5 (95% CI 0.8–2.6). - **Rosvall (5,163 subjects):** Stroke risk with plaque: HR 1.3 (95% CI 0.8–2.1). IMT top vs. bottom third: HR 2.5 (95% CI 1.2–5.4). - **ARIC men (5,552 subjects):** Heart attack risk with IMT ≥1.0 mm: HR 1.9 (95% CI 1.3–2.7). - **ARIC women (7,685 subjects):** Heart attack risk with IMT ≥1.0 mm: HR 5.1 (95% CI 3.1–8.4). - **ARIC women (7,685 subjects):** Stroke risk, IMT <0.6 vs. >1.0 mm: HR 8.5 (95% CI 3.5–20.7). - **ARIC men (6,349 subjects):** Stroke risk, IMT <0.6 vs. >1.0 mm: HR 3.6 (95% CI 1.5–9.2). - **Tromsø study (6,257 subjects):** Heart attack risk, TPA top vs. bottom third: HR 2.5 (95% CI 2.1–3.0). - **Tromsø men (6,226 subjects):** Heart attack risk, TPA top vs. bottom third: HR 1.6 (95% CI 1.04–2.4). - **Tromsø women (6,226 subjects):** Heart attack risk, TPA top vs. bottom third: HR 4.0 (95% CI 2.2–7.2). - **Tromsø men (6,226 subjects):** Heart attack risk, IMT top vs. bottom quarter: HR 1.7 (95% CI 0.98–3.1). - **Tromsø women (6,226 subjects):** Heart attack risk, IMT top vs. bottom quarter: HR 2.9 (95% CI 1.1–7.7). - **Tromsø men (6,844 subjects):** Stroke risk, TPA top vs. bottom third: HR 1.7 (95% CI 1.2–2.5). - **Tromsø women (6,844 subjects):** Stroke risk, TPA top vs. bottom third: HR 1.6 (95% CI 1.04–2.5). - **Tromsø men (6,844 subjects):** Stroke risk, IMT top vs. bottom quarter: HR 1.4 (95% CI 0.8–2.4). - **Tromsø women (6,844 subjects):** Stroke risk, IMT top vs. bottom quarter: HR 1.3 (95% CI 0.7–2.3). - **MESA (6,698 subjects):** Cardiovascular disease risk, IMT top vs. bottom quarter: HR 1.7 (95% CI 1.2–2.5). - **MESA (4,955 subjects):** Cardiovascular disease risk with carotid score: HR 1.2 (95% CI 1.2–1.4). ### Coronary Artery Calcium Studies (for Comparison) To understand how carotid ultrasound compares with the established coronary calcium test, it helps to know what the calcium data show. Coronary artery calcium (CAC) scoring uses CT scans to measure calcified plaque in the heart's arteries. Major studies found: - **Raggi (10,377 subjects):** Mortality prediction AUC 0.72–0.78, p = 0.001. - **Detrano (6,772 subjects):** Major adverse cardiovascular events AUC 0.79–0.83, p = 0.009. - **Arad (4,903 subjects):** Major adverse cardiovascular events AUC 0.68–0.79, p = 0.001. - **Erbel (4,129 subjects):** Major adverse cardiovascular events AUC 0.65–0.76, p = 0.001. - **MESA (6,814 subjects):** Major adverse cardiovascular events AUC 0.75–0.80, p = 0.001. - **MESA (6,698 subjects):** Cardiovascular disease risk, top vs. bottom quarter of calcium: HR 4.4 (95% CI 2.8–6.8). - **MESA (4,955 subjects):** Cardiovascular disease risk: HR 1.78 (95% CI 1.16–1.98). - **MESA (6,814 subjects):** With calcium score of 0: events in 1.3–5.6% of subjects. With calcium score >300: events in 13.1–25.6%. ### Meta-Analyses: Combining the Evidence Several comprehensive meta-analyses have pooled data from multiple studies to compare imaging methods head-to-head. **Den Ruijter and colleagues** (2012) analysed **14 population-based cohorts with data from 45,828 subjects**, comparing common carotid IMT with the Framingham risk score. They found only a modest improvement in reclassification and hazard ratio, but **no significant improvement in AUC**: Framingham AUC 0.76 (95% CI 0.75–0.76) vs. carotid IMT AUC 0.76 (95% CI 0.75–0.77). **Inaba and colleagues** published a meta-analysis of **11 population-based studies including 54,336 patients**. Compared with carotid IMT, **carotid plaque was a significantly better predictor of future heart attack**, with AUCs of 0.61 and 0.64, respectively (p = 0.04). The relative diagnostic odds ratio was 1.4 (95% CI 1.1–1.8; p = 0.04), meaning carotid plaque testing was 40% more accurate at distinguishing future heart attack victims from those who remained event-free. ## Carotid Plaque vs. Coronary Calcium: Head-to-Head Comparisons While earlier outcome studies compared one imaging method with traditional risk factors, two large-scale studies—**BioImage** and **MESA**—directly compared coronary calcium scoring with carotid ultrasound imaging in the same patients. The **BioImage study**, involving **5,808 healthy subjects** and published in 2015 by Baber and colleagues, directly compared the total volume of carotid plaques (measured with the Philips iU 22 ultrasound system) with the presence and amount of coronary calcium. In a direct comparison, the predictive power for cardiovascular events was **non-inferior** (equally good) in a low-to-intermediate-risk population. This is significant because coronary calcium scoring requires CT scanning (which involves radiation), while carotid ultrasound is radiation-free. The **MESA study**, which included **6,779 healthy subjects** and was published by Gepner and colleagues in 2015, compared the presence of coronary calcium with carotid plaque and carotid IMT above the 75th percentile to predict cardiovascular events. The results were striking: **only coronary calcium and carotid plaque presence were predictive—carotid IMT was not**. For the prediction of stroke or transient ischemic attack, **only the presence of carotid plaques was predictive** after 9.5 years of observation time. This means that if you want to know your stroke risk, looking for carotid plaque is more informative than measuring IMT. ## Can Medical Treatment Reverse or Slow Carotid Atherosclerosis? In a meta-analysis of **41 randomised trials including 18,307 participants** published in 2010, active treatment (such as statins or blood pressure medications) **significantly reduced cardiovascular events and all-cause death**. However, there was **no significant relationship between IMT reduction and cardiovascular events**—meaning that even when treatment didn't visibly shrink the artery lining, it still prevented heart attacks and strokes. This may seem counterintuitive, but it suggests that the benefits of treatment go beyond what ultrasound can measure in the artery wall. This finding was later confirmed in a second meta-analysis by Goldberger and colleagues. However, it was **not confirmed in the IMPROVE-IT study**, which included **3,703 high-risk patients** (average Framingham risk score of 22%, meaning a 22% risk of a heart event within 10 years). In that study, carotid IMT and its progression—but not carotid plaque—led to significant improvements in risk reclassification. The differing results highlight that research is still evolving on which measurement best reflects treatment success. ## What Should Be Measured: IMT, Plaque, or Calcium? Cardiovascular risk increases with carotid plaque burden quantified as TPA. Spence performed a study with a **5-year observation time** measuring the outcomes of heart attack, stroke, or vascular-related death and found that TPA strongly predicted these events. Regardless of traditional risk factors, structural arterial changes revealed by atherosclerosis imaging are associated with adverse cardiovascular outcomes. This is important because although screening with atherosclerosis imaging has **not yet received a Class I (highest-level) recommended indication in primary care**, the reality is that **most cardiovascular events occur in people who are NOT at high cardiovascular risk as categorised by traditional risk factors**. By inference, additional testing may be helpful in further cardiovascular risk stratification—especially for those in the "intermediate risk" grey zone. The inclusion of carotid plaque quantification into cardiovascular risk prediction has significantly improved discrimination and reclassification of patients in primary care. Carotid plaque is caused by atherosclerosis, which involves the accumulation of foam cells, smooth muscle cells, calcifications, macrophages, lipid cores, and a fibrous cap within the artery wall. Several factors influence the choice of one test over another: - Expertise and availability of the technology - Cost of the procedure - Radiation burden (ultrasound has none; CT scans do) - Validity and reproducibility - Feasibility and how quickly the test can be performed - The ability to track atherosclerosis over time to observe treatment effects In the authors' opinion, **carotid TPA is probably the most suited measurement for clinical practice**, followed by a search for femoral (leg) bifurcation plaque, aortic plaque, the use of the ankle-arm index, or measurement of plaque height with ultrasound in various vascular beds. More sophisticated tests are often time-consuming and costly or involve radiation exposure, though it has recently been shown that radiation exposure from CT can be reduced. The acquisition of IMT is technically demanding: it requires an ECG signal to capture images during diastole (the resting phase of the heartbeat) and a room temperature of **22–25°C**. Importantly, plaques should **not** be excluded from measurements because including them improves predictive accuracy for cardiovascular events. A comparative study by Laclaustra and colleagues used coronary calcium (score >0 for presence and >300 for extent) as the "gold standard" and compared the ability of traditional risk factors, 3D carotid plaque volume, and 3D femoral plaque volume to correctly detect coronary calcium in the same subjects. According to this study, **both carotid and femoral plaque were better markers for the presence and extent of coronary calcifications than traditional risk factors**, and there was a tendency toward better performance of femoral over carotid plaque, especially in smokers. This suggests that checking the leg arteries may add value, particularly for people who smoke. The authors also present the mathematical framework (Bayes' theorem) for combining imaging results with traditional risk assessment. The post-test probability calculations are: - Post-test probability (test positive) = (Prevalence × Sensitivity) / [(Prevalence × Sensitivity) + (1 – Prevalence) × (1 – Specificity)] - Post-test probability (test negative) = [Prevalence × (1 – Sensitivity)] / [(Prevalence × (1 – Sensitivity)) + (Specificity × (1 – Prevalence))] In plain language, this approach lets doctors update a patient's risk estimate based on whether the carotid ultrasound finds plaque. A positive scan in a patient with borderline risk can "reclassify" them into a higher-risk category that warrants more aggressive treatment. ## Clinical Implications: What This Means for You The evidence strongly supports the value of carotid ultrasound for improving cardiovascular risk prediction. Key takeaways for patients include: - **Carotid plaque presence matters more than IMT alone.** Multiple large studies show that plaque is a more powerful predictor of heart attacks and strokes than the thickness of the artery lining. - **Carotid ultrasound performs as well as coronary calcium scoring.** The BioImage and MESA studies directly demonstrated that carotid plaque measurement is non-inferior to coronary calcium for predicting cardiovascular events—without the radiation exposure of CT scanning. - **Women may benefit greatly.** In the Tromsø study, the risk of heart attack for women in the highest TPA third was 4.0 times that of the lowest third (95% CI 2.2–7.2), compared with 1.6 for men—a remarkable difference. - **Stroke risk is especially tied to carotid plaque.** In the MESA study, only carotid plaque presence (not coronary calcium or IMT) predicted stroke/TIA after 9.5 years. - **Treatment can help even if IMT doesn't change.** The meta-analyses showed that active treatment reduces events and death even when visible changes in IMT are absent—so don't be discouraged if a follow-up scan shows little change. The European Joint ESC (European Society of Cardiology) guidelines now state that carotid artery scanning **should be considered for adjusting the level of risk, especially in intermediate-risk subjects**. This is an important shift toward personalised medicine—treating the actual disease rather than just the risk factor profile. ## Limitations: What the Research Cannot Tell Us While the evidence is compelling, important limitations must be acknowledged: - **No uniform definition of plaque.** Different studies used different thresholds for defining plaque, making direct comparisons across studies difficult. - **Conflicting results on IMT.** Some large studies (such as the Lorenz 2010 study and the Den Ruijter meta-analysis) found that IMT did not improve prediction beyond traditional risk models, although these studies often had low plaque prevalence or focused on the common carotid artery only. - **IMT reduction ≠ event reduction.** The 2010 meta-analysis of 41 trials showed no significant relationship between IMT reduction and cardiovascular events, suggesting IMT may not be a good surrogate marker for treatment success. - **Not yet a Class I recommendation.** Despite strong evidence, carotid ultrasound screening has not received the highest-level endorsement in primary care guidelines, in part due to concerns about cost-effectiveness and whether screening leads to better outcomes in unselected populations. - **Technical variability.** IMT measurement requires strict protocols (ECG gating, temperature control, specific artery segments), which limits its reproducibility in routine clinical settings. - **Observational nature.** Much of the outcome data comes from observational cohort studies, which can show associations but cannot prove that acting on the test results improves outcomes. - **Limited field of view.** The 3D TPV technique covers only 3.8 cm of the carotid artery and may miss plaques located outside that range, though TPA captures a longer segment. ## Frequently Asked Questions ### What is carotid ultrasound and what does it measure? Carotid ultrasound is a safe, painless imaging test that uses a handheld probe on the neck to measure fatty plaque buildup in the neck arteries. It shows the actual disease, not just risk factors. Directly seeing plaque helps doctors predict heart attacks and strokes more accurately than traditional risk calculators alone. ### Why might I need carotid ultrasound if my cholesterol and blood pressure are normal? Many people who have a first heart attack or stroke were previously labeled 'low risk' by standard calculators like PROCAM and SCORE. Carotid ultrasound can find plaque that those calculators miss. Measuring plaque, rather than only risk factors, may reclassify you into a more accurate risk category and lead to better prevention. ### How does carotid ultrasound compare with coronary calcium scoring? In head-to-head studies like BioImage and MESA, carotid plaque measurement was equally good at predicting cardiovascular events as coronary calcium scoring—but without radiation. For stroke risk specifically, only carotid plaque presence, not coronary calcium or IMT, was predictive after 9.5 years in the MESA study. ### What is the difference between carotid IMT and carotid plaque? IMT is the thickness of the artery's inner two layers, while plaque is a focal thickening or buildup of fatty material. Many large studies show plaque is a stronger predictor of heart attacks and strokes than IMT alone. Including plaque in measurements improves predictive accuracy compared to measuring just IMT. ### Can carotid ultrasound predict my risk of stroke specifically? Yes. In the MESA study, only the presence of carotid plaque predicted future stroke or transient ischemic attack—not coronary calcium or IMT. Other studies, such as the Japanese 1995 study and the Tromsø study, also found that carotid plaque and stenosis predicted ischemic stroke. Measuring plaque helps assess stroke risk. ### Will treatment help even if my follow-up ultrasound shows no change in IMT? Yes. A meta-analysis of 41 randomized trials with 18,307 participants found that active treatment significantly reduced cardiovascular events and death, even when there was no visible reduction in IMT. So don't be discouraged if a follow-up scan shows little change; treatment still prevents heart attacks and strokes. ### What are the limitations of carotid ultrasound for risk prediction? There is no uniform definition of plaque, and studies used different thresholds. Some large studies found IMT did not improve prediction, and IMT reduction does not equal fewer events. Carotid ultrasound is not yet a Class I recommended screening test for everyone. Technical variability and limited field of view also matter. --- Publisher: Diagnostic Detectives Network (https://diagnosticdetectives.com) — independent multi-expert medical second opinions, worldwide, private-pay. Author byline: Anton Titov, MD, PhD. Contact: https://diagnosticdetectives.com/pages/contact Canonical page: https://diagnosticdetectives.com/products/seeing-the-problem-before-it-happens-how-carotid-ultrasound-helps-predict-heart-attacks-and-strokes